Abstract
Heart failure (HF) is a progressive syndrome with significant morbidity and mortality, necessitating the development of additional treatment modalities. This review provides a comprehensive overview of non-valvular transcatheter interventions that have seen rapid growth in the last decade to complement existing guideline-directed management. The report delves into the key pathophysiological processes in heart failure that these technologies target, including implantable hemodynamic monitoring (e.g., CardioMEMS, Cordella), left atrial decompression (e.g., Corvia IASD, V-Wave), neuromodulation (e.g., Barostim Neo), device-based therapy for cardiorenal syndrome, and cardiac contractility modulation. Based on current clinical evidence from pivotal trials, the review assesses the efficacy, safety, and persistent challenges of these interventions. It concludes that these advanced technologies hold significant promise for improving clinical outcomes and patient quality of life, while also highlighting the need for refined patient selection criteria and the integration of technologies like artificial intelligence to optimize their future utility.